HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Debt / NOTE 1.000% 8/1
Market price (% of par)
123.39%
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal
$620,325,460
Total reported market value
$871,115,291
Principal change
+$18,540,160
Market value change
-$1,322,727
Number of holders
62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

As of 30 Sep 2025, 62 institutional investors reported holding $620,325,460 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1.

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2025 Q4 $5,082,000 $5,856,137 +$456,280 123.39% 2
2025 Q3 $620,325,460 $871,115,291 -$1,322,727 140.75% 62
2025 Q2 $655,300,300 $816,966,757 -$27,562,043 114.09% 75
2025 Q1 $647,508,446 $828,761,473 +$4,645,091 128.12% 77
2024 Q4 $671,776,260 $729,242,599 -$63,107,224 108.09% 76
2024 Q3 $680,159,400 $810,230,960 +$105,251,634 118.97% 75
2024 Q2 $23,971,837,400 $716,617,672 +$791,231 111.16% 72
2024 Q1 $18,852,196,590 $642,487,786 -$1,980,520,761 97.4% 71
2023 Q4 $0 $0 -$14,082,000 123.39% 0
2023 Q3 $15,752,492,283 $631,952,021 +$552,410,785 93.7% 63